Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00599820
First received: June 30, 2006
Last updated: January 23, 2008
Last verified: January 2008
  Purpose

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks


Condition Intervention Phase
Angioid Streaks
Choroidal Neovascularization
Drug: Intravitreal Bevacizumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • BCVA
  • Fluoresceine Angiography
  • Optical Coherence Tomography

Study Start Date: November 2005
Estimated Study Completion Date: May 2006
Detailed Description:

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Angioid Streaks
  • Choroidal neovascularization associated
  • Untreated patients or patients treated once with PDT

Exclusion Criteria:

  • Ocular surgery excepting uncomplicated phacoemulsification
  • Glaucoma or any other ocular pathology
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00599820

Locations
Mexico
Asociación para Evitar la Ceguera en México (APEC)
México city, Distrito Federal, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Adriana Solís-Vivanco, MD Asociación para Evitar la Ceguera en México
Study Chair: Jans Fromow-Guerra, MD PhD Asociación para Evitar la Ceguera en México
Study Chair: Mariana Martínez-Castellanos, MD Asociación para Evitar la Ceguera en México
Study Chair: Elizabeth Reyna-Castelán, MD Asociación para Evitar la Ceguera en México
Study Chair: Myriam Hernández-Rojas, MD Asociación para Evitar la Ceguera en México
Study Chair: Griselda Alvarez-Rivera, MD Asociación para Evitar la Ceguera en México
Study Director: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en México
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00599820     History of Changes
Other Study ID Numbers: APEC 010
Study First Received: June 30, 2006
Last Updated: January 23, 2008
Health Authority: Mexico: National Institute of Public Health, Health Secretariat

Keywords provided by Asociación para Evitar la Ceguera en México:
Angioid Streaks
Choroidal Neovascularization
Bevacizumab

Additional relevant MeSH terms:
Angioid Streaks
Neovascularization, Pathologic
Choroidal Neovascularization
Retinal Diseases
Eye Diseases
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 17, 2014